Alpha Tau Medical Ltd. Reports Breakthrough Results in Head and Neck Cancer Trial

Alpha Tau Medical Ltd. (Nasdaq: DRTS), a Wilmington‑based developer of alpha‑emitter radiation therapy, announced on July 21, 2026 that its phase I/II study of Alpha DaRT® combined with pembrolizumab (Keytruda®) achieved a 100 % objective response rate (ORR) in nine evaluable elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). The data were presented at the American Head and Neck Society’s 12th International Conference on Head and Neck Cancer in Jerusalem.

Clinical Outcomes

  • Objective Response Rate: 100 % (four complete responses, five partial responses) versus a historical 19 % ORR for pembrolizumab monotherapy in this setting.
  • Median Overall Survival (OS): 18.2 months, compared with 12.3 months for pembrolizumab alone.
  • Median Progression‑Free Survival (PFS): 5.4 months, versus 3.2 months historically.
  • Safety Profile: No serious adverse events attributed to Alpha DaRT; only two mild Grade 1 events were reported.

The trial met its Simon two‑stage adaptive design threshold, with recruitment now complete. Alpha Tau is continuing discussions with the U.S. Food and Drug Administration (FDA) regarding the combination strategy.

Market Reaction and Analyst Coverage

The study’s positive results have attracted renewed analyst interest. On July 23, 2026, H.C. Wainwright reiterated a “buy” rating for Alpha Tau Medical, citing the encouraging data as a catalyst for future growth. The company’s share price, closing at $13.01 on July 21, sits below its 52‑week low of $2.87 but near the 52‑week high of $14.11, indicating a potential upward trajectory following the announcement.

Company Context

Alpha Tau Medical specializes in developing and manufacturing medical devices that deliver diffusing alpha‑emitters for conformal radiation therapy of solid tumors. With a market capitalization of approximately $1.22 billion and a negative price‑earnings ratio of –17.83, the company remains in a growth phase, focusing on expanding its clinical portfolio and regulatory approvals.

The recent data underscore Alpha Tau’s strategic emphasis on combination therapies, aligning with broader industry trends toward synergistic immuno‑radiation approaches. If FDA approval is secured, the company could broaden its product offering to a wider patient population and enhance its competitive positioning within the oncology device market.

Outlook

While the results are preliminary and derived from a small cohort, the 100 % ORR and favorable survival metrics provide a compelling signal of efficacy. Investors and clinicians alike will be monitoring subsequent confirmatory trials and FDA review outcomes closely. Should the company maintain this momentum, Alpha Tau Medical may experience a significant recalibration of its valuation and market perception in the coming months.